FDA PMA FDA Class 3 Approved 🇺🇸 United States

Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations

PMA: P990040 · Supplement: S033 · Decision Jul 2, 2024
Classifications
1
FEI Numbers
5
Registration Numbers
5

Basic Information

Device Name
Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations
Trade Name
TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System
PMA Number
P990040
Supplement Number
S033
Device Class
FDA Class 3
Product Code
KGG
Generic Name
tissue adhesive for use in embolization of brain arteriovenous malformations
Medical Specialty
Unknown
Advisory Committee
Neurology
Decision
Approved
Decision Code
APPR
Decision Date
July 2, 2024
Date Received
April 5, 2024
Supplement Type
Normal 180 Day Track
Supplement Reason
Labeling Change - Indications/instructions/shelf life/tradename
Expedited Review
N

Advisory Committee Statement

approval for a legal manufacturer change, updates to the Directions for Use (DFU) labeling, and a transition to electronic DFU only with removal of the paper DFU with the packaged devices. The P990040/S033 submission requested to update the legal manufacturer to Cerenovus, Inc.; however, this ownership change was already made under the P990040/A015 submission and acknowledged in the FDA letter dated September 12, 2023, where the legal manufacturer and entity responsible for the PMA was modified from Medos International SARL to Cerenovus, Inc. You also verified by email on April 16, 2024, during the P990040/S033 review that no changes were made to the sites where manufacturing of the TRUFILL n-BCA Liquid Embolic System is performed due to the ownership change.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
KGG Tissue Adhesive For Use In Embolization Of Brain Arteriovenous Malformations